Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioWorld
Orion
Before the decision to wind down, the company had high hopes for its Orion visual cortical prosthesis system. The company saw the potential for the product to provide useful artificial vision to individuals blind from many causes, such as glaucoma, eye injury, diabetic retinopathy, optic nerve disease or injury and retinitis pigmentosa.
Indeed, during the company’s March 19 fourth-quarter earnings call, COO Pat Ryan provided an update on the company’s Orion early feasibility study. Specifically, it had wrapped up the 12-month testing for the sixth and final subject in February. Ryan detailed some results, noting that on square localization, 83% of individuals scored significantly better with the device on than off. All individuals scored significantly better with the device on than off on direction of motion.
“From a safety perspective, as previously shared, there was one serious adverse event in seven nonserious adverse events over the same time period. These results are extremely encouraging, and we believe sufficient to support moving forward with a pivotal study in the U.S.,” Ryan said.
The company had reached an agreement with the U.S. FDA on the primary efficacy endpoint for the pivotal trial, which will be FLORA [Functional Low Vision Observer Rated Assessment] 20. As of that date, three of 15 subjects have begun participation in the FLORA 20 validation. “However, due to COVID-19 social distancing protocols, we have suspended validation efforts until further notice,” he said at the time.
Kyle Bauser from Dougherty & Co. asked whether COVID-19 had had an impact on the IDE application, given that it was now slated for the first half of next year. Ryan said no, adding that the company was being conservative in light of ongoing discussions with the FDA.
Competition
For its part, a big competitor of Second Sight, Paris-based Pixium Vision SA, reported March 31 positive follow-up data from a feasibility trial of the Prima system in patients with dry age-related macular degeneration (AMD). Specifically, the Prima system sustainably elicited light perception in all four dry AMD patients with favorable safety profile. The company said the results build on the previously reported positive 12-month clinical data. The Prima system is intended to partially replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina. Those then transmit the visual information to the brain via the optic nerve.
But COVID-19 is having an impact on this company as well. Pixium reported March 23 that it had decided to postpone continuing its feasibility studies in France and the U.S., aside from ongoing safety monitoring. It added that the initiation of the PRIMAvera pivotal study with the Prima system in dry AMD may be delayed.
Will McGuire, President and Chief Executive Officer, John T. Blake, Chief Financial Officer, and Pat Ryan, Chief Operating Officer, will host a conference call to discuss the results as follows:
Date Thursday, March 19, 2020
Time 4:30 p.m. ET
Toll free (U.S.) (800) 710-8126
International (720) 634-2491
Webcast (live and replay) www.secondsight.com under the ‘Investors’ section.
The archived webcast will be available for 30 days via the aforementioned URL.
Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEO
LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the departure of Will McGuire, President and Chief Executive Officer (“CEO”), effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board.
Effective March 27, 2020, Gregg Williams, the Company’s Chairman of the Board, will assume the role of Acting CEO. Reporting to Mr. Williams will be John T. Blake, Chief Financial Officer and Pat Ryan, Chief Operating Officer. The Board is initiating a search process in order to identify the future CEO.
“I have tremendous confidence in John’s and Pat’s abilities and I look forward to working together with them to lead the Second Sight team into this exciting new phase of our journey,” stated Gregg Williams.
“I would like to take this opportunity to thank Will for his many contributions to Second Sight over the past four and a half years as President and CEO, during which time he led the implementation of our strategy to focus on the development and advancement of our breakthrough Orion® Visual Cortical Prosthesis System. I also look forward to his continued contributions as a board member. I believe that the 12-month results from the Orion Early Feasibility Study are extremely encouraging, and we continue to make great progress advancing this life-changing neuro-modulation technology, not only in pursuit of our quest to treat all forms of blindness, but eventually in many other fields using derivatives of the same basic core technologies and software,” continued Mr. Williams.
“It has been my honor to lead the incredibly talented team at Second Sight,” said Will McGuire. “I am extremely proud of the accomplishments we have achieved in the successful advancement of Second Sight’s breakthrough neuro-modulation technology, which has the potential to provide useful artificial vision to virtually all profoundly blind individuals. I remain excited for the opportunity to continue supporting the team in my role as a board member.”
my biggest concern for EYES is.......
The company going private, especially before FDA approval of Orion
With insiders controlling significantly more than 50% of the shares, at what price?
Will they try to steal the company???
The closing price yesterday was $3.89
divided by 8, the pre r/s price is .49
December 31, 2019 Second Sight Medical Products Inc. (the “Company”) filed its Second Amendment to Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of California to effect a one-for-8 (1:8) reverse stock split of all issued and outstanding shares of the Company’s common stock, no par value per share (the “Common Stock”), and also to effect a one-for-8 reverse split of the Company’s warrants (the “Warrants”), (the “Reverse Stock Split”). The Reverse Stock Split is intended to bring the Company into compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(a)(2). The Reverse Stock Split was approved by the Company’s majority stockholders on November 26, 2019.
As a result of the Reverse Stock Split every eight shares of Common Stock and every eight Warrants will be combined and converted into one share of Common Stock and one Warrant, respectively. The Company anticipates that its Common Stock and Warrants will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the market open on January 6, 2020. The trading symbols for the Common Stock and Warrants will remain “EYES” and “EYESW.” Following the Reverse Stock Split the new CUSIP number for the Common Stock is 81362J209 and the new CUSIP number for the Warrants is 81362J126.
The Reverse Stock Split reduces the number of shares of common stock issued and outstanding from approximately 125.1 million to approximately 15.6 million and reduces the number of trading Warrants outstanding from approximately 61.4 million to 7.7 million. The authorized number of shares of common stock did not change as a result of the Reverse Stock Split. The Reverse Stock Split affects all issued and outstanding shares of the Company’s Common Stock, stock purchase warrants, and options and other outstanding awards issued under the Company’s equity incentive plans. The Reverse Stock Split affects all stockholders and warrant holders uniformly and will not alter any stockholder’s percentage interest in the Common Stock or any warrant holder’s percentage interest in the Warrants, except for adjustments that may result from the treatment of fractional shares and fractional warrants as described below.
The shorts(4m shares+) are controlling the price and keeping the price under $1
Whether or not we ask and/or get another 6 month extension from doing a R/S, our mkt. cap is 97M which is a joke, IMHO.
Second Sight has since been working to bring the Argus II Retinal Prosthesis System to patients around the world. By 2020, our Centers of Excellence will serve people with RP across most of the U.S, supported by more than 25 centers across the globe; we continue to research and develop new technologies and therapies for people affected by retinitis pigmentosa.
CBS NEWS September 18, 2019, 10:58 AM
Scientific breakthrough may eventually allow many blind people to SEE
A scientific breakthrough may eventually allow many blind people to see. A handful of volunteers are already seeing the promise of a new device, about 18 months into a five-year clinical study.
One of those volunteers is Jason Esterhuizen. The South African lost his sight in a car accident when he was 23 years old.
"Lost control of the car," Esterhuizen said. "The car hit the curve and I just hit the steering wheel and the window and went out the sunroof."
Injuries from the crash left Esterhuizen in a world of total darkness.
"I think in the first couple of years of being blind it was just you have to accept the fact that you're blind," he said.
That changed when a friend of his heard about a clinical trial only for people who could once see but became blind, starting half a world away at the University of California, Los Angeles. Dr. Nader Pouratian leads the study of an experimental device called the Orion.
Here's how it works. Using a camera attached to a pair of sunglasses, Orion captures images a person would see and then sends the data through a handheld device to an implant that's been surgically inserted into the visual part of the brain. The implant then turns those images into dots of light the patient can see.
"It can be various shapes, it could be a circle, it could be an oval," Pouratian said. "It could be a moving line."
Esterhuizen is one of only six people in the world who qualified for the study to receive the implant.
"The first time that I saw a little white dot, I was speechless," Esterhuizen said. "It was the most beautiful thing I have ever seen."
While not restoring sight in the traditional sense, what he can "see" are flashes of light.
"If I look around, I can perceive movement, I can see some light and dark," Esterhuizen said. "I can tell you whether a line is vertical or horizontal or at a 45-degree angle."
The device not only allowed Esterhuizen to regain a small part of his vision, but some true independence.
"I cook, I clean. I can take out the trash," Esterhuizen said. "I can sort laundry, but just the darks from the lights. No color yet."
It even helps him in going for a stroll outside by himself.
"If I look down, I can see flashing lights," he said.
In fact, the study has gone so well in Esterhuizen's case that sometimes even he doesn't realize how amazing it's been. Esterhuizen was nonchalantly telling Pouratian about a night when he was at a dark bar and could see the bartender, in a white shirt, walking toward him.
"And I just saw two little dots lighting up and then three and then five. Then she was right in front of me and she was all shiny and I thought, wow that's cool."
"And I said, 'Do you realize what you just said?!'" Pouratian said.
It's a glimpse into the future that could give countless people a second chance at sight.
© 2019 CBS Interactive Inc. All Rights Reserved.
Anyone listen to 3rd quarter conference call?
Earnings at this point are irrelevant IMHO
Recent Corporate Highlights:
• Reached agreement with the U.S. Food and Drug Administration (“FDA”) regarding the primary efficacy endpoint to be used in the Orion® Visual Cortical Prosthesis System (“Orion”) pivotal trial;
• Presented additional positive data from the Company’s Early Feasibility Study of Orion at three scientific conferences in October: the American Academy of Ophthalmology (AAO), the Congress of Neurological Surgeons (CNS), and the Society for Neuroscience (SfN);
• Met with Centers for Medicare and Medicaid Services (“CMS”) to discuss future reimbursement for artificial vision to include the critically important post-surgical training and rehabilitation; and
• Received a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM) in collaboration with the Johns Hopkins University Applied Physics Laboratory (APL).
“Our ongoing discussions with the FDA are proceeding well, and we are pleased to have reached agreement on the primary efficacy endpoint for the Orion pivotal trial. This endpoint is a new version of the FLORA assessment tool used in the Argus II trial and is designed to measure the technology’s impact to orientation, mobility and activities of daily living. Our efforts are currently focused on finalizing agreement with the FDA on the primary safety endpoint by year end. We are also engaged in productive dialogue with CMS about reimbursement for the critically important post-surgical training for Orion users, in an effort to ensure that patients are able to achieve the greatest benefit from the device,” stated Will McGuire, President and Chief Executive Officer of Second Sight.
“Orion has received excellent coverage in the media recently, as awareness and excitement builds for this innovative, life-changing device. R&D efforts continue to focus on enhancements to Orion that are required for a pivotal trial and ultimately for commercialization. Most importantly, the Orion subjects in our feasibility study are doing well, and we look forward to advancing this important technology and making it available to the large population of blind individuals who can benefit,” concluded McGuire
looking for another trade if it gets back into the 80's
Second Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference Call
Thursday, November 14, 2019
Time
4:30 p.m. EST
Toll free (U.S.)
(800) 771-6759
International
(212) 231-2937
Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its financial results for the third quarter of 2019 on Thursday, November 14, 2019, after the close of the U.S. financial markets.
Will McGuire, President and Chief Executive Officer, and John T. Blake, Chief Financial Officer, will host a conference call to discuss the results as follows:
Webcast (live and replay)
www.secondsight.com under the ‘Investors’ section.
A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21933121. The archived webcast will be available for 30 days via the aforementioned URL.
About Second Sight
Second Sight Medical Products, Inc. (EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland. More information is available at www.secondsight.com.
"The Company anticipates negotiating the clinical & regulatory pathway to commercialization with the FDA as part of the Breakthrough Devices Program"
This is part of the latest PR. Any shareholders have an idea of a timeline? I have contacted the company and asked them.
This could be the impetus for the stock to breakout as we have been basing here for a while
Does anyone here think our only shot is to be bought out?
Don't see anything else in the near future
Attending numerous conferences and changing mgmt. personnel
but no upward movement until big contract signed and/or take over.
All in IMHO
Second Sight Announces $2.4 Million, Four-Year Grant from National Institutes of Health to Develop Spatial Localization and Mapping Technology
Great news
Having this type of relationship with Federal Agencies will be
significant in aiding EYES in getting FDA approval much faster IMHO
getting close to my entry but.....
only for a trade at this point.
Still expect the drop to low 90's
we shall see
EYES will be attending these 2 conferences in September
EURETINA 2019 Congress
Start date: September 5, 2019
End date: September 8, 2019
visit website EURETINA 2019 Congress
For Healthcare Professionals
Retinal Society 52nd Scientific Program
Start date: September 11, 2019
End date: September 15, 2019
visit website Retinal Society 52nd Scientific Program
looks like....
a retracement below a $1
looking to buy at .90 - .95
IMHO
Highlights from Today's 2nd qtr PR
As of June 30, 2019, Second Sight had $25.2 million in cash and cash equivalents. The Company continues to expect its cash to fund operations into the second quarter of 2020.
Recent Financial and Corporate Highlights:
• Continued progress on development of the Orion® Visual Cortical Prosthesis System (“Orion”); ?Met with the U.S. Food and Drug Administration (“FDA”) in July to provide an update on the Orion Early Feasibility Study, and to discuss pivotal study design and post-market requirements;
? Hired 15 full-time employees year-to-date to support R&D and clinical research priorities;
• Reduced commercial expenses by 41% in the second quarter of 2019 compared to the prior year quarter;
• Notified Argus implanting centers of the Company’s intent to suspend Argus II production by the end of 2019;
• Presented positive topline 12-month results on the Company’s Early Feasibility Study of the Orion Visual Cortical Prosthesis System at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting on June 25, 2019;
•Centers for Medicare and Medicaid Services (“CMS”) released its FY 2020 Inpatient Prospective Payment System (IPPS) Final Rule. In this rule, CMS finalized its proposal to create an alternative payment pathway for innovative technologies with an FDA Breakthrough Devices Designation such as Orion;
• Implanted 11 Argus II systems worldwide; and
• Reported net sales of $1.3 million in the second quarter of 2019.
“We continue to make excellent progress with the development of the Orion platform and are working closely with the FDA to define pivotal study and post-market requirements. We commend CMS for creating a streamlined reimbursement pathway for innovative devices such as Orion with an FDA Breakthrough Devices Designation. In preparation for Orion’s potential commercial launch, we are beginning to engage CMS and private payors in order to define the appropriate reimbursement pathways,” stated Will McGuire, President and Chief Executive Officer of Second Sight.
“Second Sight continues to pioneer the development of neuromodulation technology for artificial vision. The interim data from our Orion Visual Cortical Prosthesis Early Feasibility Study compare favorably to Argus and further support our belief in Orion’s potential to treat nearly all forms of blindness,” concluded McGuire.
Second Half 2019 Key Objectives
• Execute Orion R&D implant and externals projects;
• Finalize agreement with the FDA regarding Orion’s clinical and regulatory path;
• Engage and expand discussions with CMS and private payors while developing a comprehensive reimbursement strategy for Orion in the U.S.;
• Submit Argus 2s, our next-gen externals, to the FDA for U.S. regulatory approval; and
• Add key talent to support our Orion programs and develop a plan for high-volume manufacturing.
About Second Sight
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland. More information is available at www.secondsight.com.
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion® Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system. The Company anticipates enrolling additional feasibility subjects in 2019 while simultaneously negotiating the clinical and regulatory pathway to commercialization with the FDA as part of the Breakthrough Devices Program.
Conference call after the close on Tuesday Aug. 6th
Hopefully update on the trials
GLTAL
Delisting averted as per today's 8K
On July 25, 2019, the Company received notice from Nasdaq indicating that, while the Company has not regained compliance with the minimum bid price requirement, staff of Nasdaq has determined that the Company is eligible for an additional 180-day period, or until January 20, 2020 to regain compliance. Staff’s determination was based on (i) our meeting the continued listing requirement for market value of our publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and (ii) our providing written notice to Nasdaq of our intent to cure the deficiency during this second compliance period, if necessary by effecting a reverse stock split. If at any time during this second 180-day period the closing bid price of the Company’s common stock is at least $1 per share for at least a minimum of 10 consecutive business days Nasdaq staff have stated they will provide written confirmation of compliance. If compliance cannot be demonstrated by January 20, 2020, Nasdaq staff will provide written notification that the Company’s securities will be delisted. At that time, the Company may appeal staff’s determination to a hearings panel. We can give no assurance that the Company will regain or demonstrate compliance by January 20, 2020.
EYES attending ASRS conference
Hopefully further trial updates will be reported
ASRS 37th Annual Meeting
Start date: July 26, 2019
End date: July 30, 2019
visit website ASRS 37th Annual Meeting
Not sure what to make of this stock and the news
been disappointed in the past
expect the stock to go back below $1 and build a base
But, who knows
Looking forward to seeing more trial updates for Orion and feedback from FDA
Gregg Williams always has the option of taking EYES private if he doesn't see value being public
He owns 79M shares as he has invested more than $100M in the company
As Gregg Williams continues to purchase shares daily, we can only hope that a catalyst will develop soon.
GLTAL
Basically, EYES is a private company with just shorts and program traders(mm) playing their games. I also agree delisting to the OTCBB is better than a r/s.
I am hoping a catalyst will evolve to move the stock up.
who knows what or when it will happen.
Either way, I can wait
GLTAL
Great find and read
Getting approval from the Breakthrough Devices Program,with the FDA, will be the catalyst for commercialization and surge in the stock price.
Any thoughts as to a timeframe? Late 2019? Early 2020?
GLT all investors and patients
Researchers Present Latest Positive Results of Second Sight’s Orion Visual Cortical Prosthesis Feasibility Study
Business WireJune 25, 2019
LOS ANGELES & NEW YORK--(BUSINESS WIRE)--
Study Investigators from UCLA and Baylor Provide Latest Study Update at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting
Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, announced that 12-month results from the Company’s Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) will be presented today at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting in New York City. On both the primary and secondary outcome measures, latest results at 12 months have been positive.
The study’s principal investigators, Nader Pouratian, MD, Ph.D. of Ronald Reagan UCLA Medical Center (“UCLA”), and Daniel Yoshor, MD of Baylor College of Medicine (“Baylor”), are presenting the topline data. Orion is a breakthrough technology intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion converts images captured by a miniature video camera mounted on glasses into a series of small electrical pulses transmitted wirelessly to electrodes implanted directly on the visual cortex of the individual subject’s brain.
The first human subject was implanted with Orion in January 2018. A total of six subjects have been implanted in the Orion Early Feasibility Study, including four subjects at the UCLA site in Los Angeles and two subjects at the Baylor site in Houston. There are five male subjects and one female subject, with a median age of 48 and an average of 13 months since implant. Study subjects are completely bilaterally blind. Causes of vision loss among participants include congenital glaucoma, head trauma, endophthalmitis and optic neuropathy.
The primary outcome measure of the Orion Early Feasibility Study is safety. Secondary outcome measures include the ability to produce phosphenes, assess the long-term functionality of the device and evaluate the benefit to patients in terms of visual function, functional vision and quality of life.
“We are pleased with the continued favorable progress being made in the Orion Early Feasibility Study among the six study participants. The first four subjects have now reached 12 months post-implant, and participants appear to be making steady improvements in their ability to perform everyday tasks and successfully meet the study’s functional vision endpoint goals. It is also encouraging to see that when compared with similar Argus II feasibility study results at the 12-month mark, the Orion study participants are doing as well as or better than Argus II participants in most measurements, such as the Functional Low-Vision Observer Rated Assessment (FLORA). We look forward to continued collaboration with our study investigators and to advancing our Orion technology platform,” said Will McGuire, President and Chief Executive Officer of Second Sight.
Study Results
Safety outcomes as of the last independent medical safety monitor review:
• Only two out of six study participants have experienced an adverse device event (ADE), which, as of May 3, 2019, included one serious adverse event (seizure), five non-serious adverse events such as headache, and no unanticipated adverse device events.
Ability to see phosphenes demonstrated for all patients:
• The perception threshold measurements, which is the energy required to produce a spot of light, for all participants have remained generally consistent over time.
Preliminary performance assessment of ability to locate objects and detect motion at 12 months post-implant (four subjects measured as of June 25, 2019):
• Three out of four Orion subjects at 12 months demonstrated the ability to locate a high-contrast target significantly better with the System ON than with the System OFF (t-test, p<0.05) as measured by Square Localization.
• Three out of four Orion subjects at 12 months demonstrated the ability to determine the direction of motion of a high-contrast target significantly better with the System ON than with the System OFF (t-test, p<0.05).
Overview of real-world use of Orion:
• Four out of four Orion subjects at 12 months were rated by certified Orientation and Mobility specialists as having received positive or mild positive benefit from Orion in terms of functional vision and well-being on the FLORA.
The presentation is available on Form 8-K as filed with the U.S. Securities and Exchange Commission.
About Second Sight
Second Sight Medical Products, Inc. (EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland. More information is available at www.secondsight.com.
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion® Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system. The Company anticipates enrolling additional feasibility subjects in 2019 while simultaneously negotiating the clinical and regulatory pathway to commercialization with the FDA as part of the Breakthrough Devices Program.
Hopefully......
We will positive news from the conference
The World Society for Stereotactic and Functional Neurosurgery (WSSFN)
June 24th to the 27th
EYES is attending
Are there any longs on this board,,,,,,,,,
interested in discussing the outlook for EYES?
Announcing Our Redesigned Website
We're excited to announce a newly redesigned website, please visit www.soligenix.com to take a look. Thank you for your continued support as we rise to the challenges of rare disease treatment.
Very interesting read, I comprehend why you think FDA approval is
at least 12 months away. I certainly hope mgmt. gives us up updates on the trials.
Any thoughts as to why Gregg Williams continues to buy shares even though he owns more than 63% of the outstanding shares? 78M
shares at last purchase.
If he wanted to go private he already controls the company. Is it just that he sees this as a great opportunity?
Your response leads me to believe you have an extensive background in this area. We will hopefully get some catalyst to raise the stock price to avoid a r/s. While I do believe that we are in a "when" mode not an "if" one, price appreciation for the foreseeable future is unknown. That is probably why the maturity of the warrants was extended to 2024.
Please continue to post and update us on any insights you have. I find the fact SS is working on the higher resolution concept very important as you stated. Hopefully, management will update as well.
Good luck to us all. Especially, to those recipients of this innovative science
what do you think of early approval by FDA of ORION?
Maybe late 2019 or early 2020?
I agree with you that the financials will probably prevent any big upside move in EYES, I am hopeful that any additional raise will not be done by traditional methods. I have a feeling it will be a private placement by a large investor. But, we will see.
2 new purchases by Greg Williams
6/4 31,304 shares at .7032
6/5 31,746 shares at .6774
after reading the form 4 more closely.....
these options were awarded not purchased as compensation by the company
But, still positive with the 10 year expiration and in lieu of taking cash IMO
Did anyone see the latest purchase by Greg Williams from yesterday?
He purchased more than 250K of options that expire in 2029
Obviously he is looking long term